脑心通胶囊治疗慢性稳定性心绞痛的疗效与安全性:随机对照试验研究方案
本研究为多中心、随机、双盲、安慰剂对照临床试验,计划纳入260例慢性稳定性心绞痛患者,等比例随机接受脑心通胶囊或安慰剂治疗12周,主要结局为治疗有效率,次要结局包括中医证候积分、心绞痛严重程度分级、每周心绞痛发作次数、硝酸甘油用量、西雅图心绞痛量表评分、血清同型半胱氨酸及心血管事件发生率,同时监测安全性指标与不良事件。
要点
- 脑心通胶囊治疗慢性稳定性心绞痛的多中心随机双盲安慰剂对照试验方案。
- 计划纳入260例,治疗12周,主要结局为治疗有效率。
- 次要结局涵盖中医证候、心绞痛发作、硝酸甘油用量及心血管事件。
核心结论
- 该研究旨在评估脑心通胶囊对比安慰剂治疗慢性稳定性心绞痛的疗效与安全性。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照临床试验,计划纳入260例合格受试者,等比例随机分配。
- 经过2周导入期后,受试者接受脑心通胶囊或安慰剂(每次3粒,每日3次)治疗12周。
关键数值与推荐
- 主要结局为治疗有效率。
- 次要结局包括中医证候量化积分、心绞痛严重程度分级、每周心绞痛发作次数、硝酸甘油用量、西雅图心绞痛量表评分、血清同型半胱氨酸及心血管事件发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiovascular disease is the leading cause of mortality and morbidity worldwide, Chronic stable angina (CSA) is the main symptom of myocardial ischemia, causes increased risk of major cardiovascular events such as sudden cardiac death and myocardial infarction. Naoxintong (NXT) capsule is a classical traditional Chinese medication used to treat CSA, however, few evidence to support the wide utility of NXT capsule for the treatment of CSA. We design this study to evaluate the efficacy and safety of NXT capsule versus placebo in patients with CSA. METHODS/DESIGN: This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. A total of 260 eligible participants will be enrolled. The participants will be randomized assigned in an equal ratio to groups receiving either NXT or placebo for 12 weeks. After a 2-week run-in period, they will receive either NXT or placebo (3 pills, 3 times daily) for 12 weeks. The primary outcome is therapeutic efficacy. Secondary outcome measures include the quantitative score of TCM syndromes, severity grading of angina pectoris, the number of angina pectoris per week, nitroglycerin dosage, score of Seattle angina scale, serum homocysteine, and incidence of cardiovascular events. Safety outcomes and adverse events will be monitored throughout the trial. DISCUSSION: We designed this study in accordance with principles and regulations issued by the China Food and Drug Administration (CFDA). The results will provide clinical evidence of the efficacy and safety of NXT Capsule in the treatment of CSA. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2100044563 . Registered on 24 March 2020.
引用
- Huanjia G, Hairong C, Jieqin Z, et al. Efficacy and safety of Naoxintong capsule for treating chronic stable angina: study protocol for a randomized controlled trial. Trials. 2021. PMID: 33971940. doi:10.1186/s13063-021-05264-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。